Library > Country Reports



Having foregrounded its life sciences credentials with the establishment of manufacturing and clinical trials hubs, Spain is hoping to secure its position as a globally relevant industry player. The Iberian nation can boast an advanced healthcare system – which has…

PharmaBoardroom’s latest report, InFigures: Middle East & Africa (MENA) 2022 features up-to-date datasets from the region’s leading pharma markets and regional production hubs. MENA may be the smallest pharmaceutical market in the world, accounting for just 2 percent…

PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022 features up-to-date datasets from six major European pharma hubs. Europe is the world’s second biggest pharma market region and boasts the headquarters of some of the world’s largest pharma…

PharmaBoardroom’s latest report, InFigures: Latin America 2022 features up-to-date datasets from the region’s leading pharma markets and regional production hubs. A regional market of USD 98 billion looks set to be the fastest growing in the world over the next few…

Saudi Arabia – by many measures the cultural, social, and economic centre of the Arab and Islamic worlds – is currently undergoing a once-in-a-lifetime transformation. The ‘Vision 2030’ transformation plan is not only reshaping the Saudi economy and reducing its…

Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. With life…

On the verge of its 100th anniversary, the Republic of Turkey appears to be approaching a decisive moment in the trajectory of its healthcare industry. With a comprehensive social security system covering over 95 percent of the population already in the bag, and after more…

PharmaBoardroom’s latest report, InFigures: Asia Pacific 2021 features up-to-date datasets from the region’s leading pharma markets and regional innovation hubs. Covering everything from population health to market growth, company rankings, innovation footprints, IPOs,…

With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies…

Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European…

Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email…

A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here